Defendant
13 cases as defendant.
Class action antitrust case citing the '275 patent as part of an alleged Orange Book scheme; consolidated in the N.D. Cal. Xyrem antitrust proceeding before Judge Seeborg.
Antitrust action by New York State Teamsters Council Health & Hospital Fund against Jazz, with Roxane named as a party; consolidated into/related to the Xyrem MDL.
Antitrust/consumer class action alleging pay-for-delay. The complaint lists US 7,851,506 among the patents at issue; defendants include Roxane Laboratories, Inc.
The '306 patent was asserted; Roxane moved to dismiss the '306 claims on §101 subject-matter eligibility, which the court administratively terminated and stayed discovery on pending IPR. The case was consolidated with Roxane's '302 case on Mar 24, 2016 and settled in April 2017.
DrugPatentWatch lists 8,324,275 as asserted in Jazz Pharmaceuticals v. Roxane Laboratories; the case was resolved via the April 2017 Jazz–Roxane settlement.
Jazz sued Roxane Laboratories (later Hikma/West-Ward) asserting the '650 patent. The case was consolidated with 2:10-cv-06108 and 2:12-cv-07459 in April 2013, and the consolidated case settled April 5, 2017, granting Hikma/West-Ward an authorized generic of Xyrem beginning Jan. 1, 2023.
Second D.N.J. suit by Jazz against Roxane Laboratories involving the '106 patent. It was closed.
Hatch-Waxman ANDA suit filed by Jazz Pharmaceuticals against Roxane Laboratories concerning U.S. 7,895,059. The case was consolidated with lead action 2:10-cv-06108 and settled in April 2017.
Lead/first ANDA Hatch-Waxman case filed by Jazz Pharmaceuticals against Roxane Laboratories. The complaint expressly asserted US 7,765,107 along with other patents ('889, '219, '730, '106); the '107 claims were later invalidated via IPR2015-00547.
Lead Hatch-Waxman action asserting the '219 patent against Roxane; consolidated with several related Roxane actions. Claim construction issued 2012-09-14 and the case settled before trial.
D.N.J. Hatch-Waxman/ANDA litigation over Xyrem. Jazz identified this action as concerning patents related to the '963 patent in its mandatory notices in IPR2015-01903.
Lead consolidated Hatch-Waxman action over Xyrem sodium oxybate. The ’506 patent was among the original patents-in-suit, along with the ’431, ’889, ’219, ’059, and the ’730 family. Resolved by settlement with no final judgment on the ’506 patent.
Related Jazz v. Roxane action listed for the ’506 patent family and consolidated into 2:10-cv-06108. Resolved as part of the Roxane settlement.